| Care First Home Health Care | |
| 9315 W Sunset Road Ste 101, Las Vegas, Nevada 89148 | |
| (702) 932-5859 | |
| Name | Care First Home Health Care |
|---|---|
| Location | 9315 W Sunset Road Ste 101, Las Vegas, Nevada |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 297143 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 89002, 89011, 89012, 89014, 89015, 89030, 89031, 89032, 89044, 89052, 89074, 89081, 89084, 89085, 89086, 89101, 89102, 89103, 89104, 89106, 89107, 89108, 89109, 89110, 89113, 89115, 89117, 89118, 89119, 89120, 89121, 89122, 89123, 89128, 89129, 89130, 89131, 89134, 89135, 89138, 89139, 89141, 89142, 89143, 89144, 89145, 89146, 89147, 89148, 89149, 89156, 89161, 89166, 89169, 89178, 89179, 89183 |
| NPI Number | 1104014794 |
| Organization Name | CARE FIRST HOME CARE, LLC |
| Address | 9315 W Sunset Rd. #101, Las Vegas, NV 89148 |
| Phone Number | 702-932-5859 |
News Archive
Mirada Medical, a global leader in Artificial Intelligence software for the treatment of cancer, has announced today further global installations of DLCExpert, the world's first commercially available AI-powered auto contouring software for cancer treatment planning and the only system with over one year of clinically proven use.
LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.
Former Senate Majority Leader Tom Daschle, a South Dakota Democrat, tells Kaiser Health News that a Republican strategy to defund the health law may be an effective way for the plan's opponents to unravel it.
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.
› Verified 8 days ago
| NPI Number | 1699170928 |
| Organization Name | CARE FIRST HOME CARE, LLC |
| Address | 9315 W Sunset Rd Ste 101, Las Vegas, NV 89148 |
| Phone Number | 702-932-5859 |
News Archive
Mirada Medical, a global leader in Artificial Intelligence software for the treatment of cancer, has announced today further global installations of DLCExpert, the world's first commercially available AI-powered auto contouring software for cancer treatment planning and the only system with over one year of clinically proven use.
LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.
Former Senate Majority Leader Tom Daschle, a South Dakota Democrat, tells Kaiser Health News that a Republican strategy to defund the health law may be an effective way for the plan's opponents to unravel it.
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.
› Verified 8 days ago
| Quality Rating: |
News Archive
Mirada Medical, a global leader in Artificial Intelligence software for the treatment of cancer, has announced today further global installations of DLCExpert, the world's first commercially available AI-powered auto contouring software for cancer treatment planning and the only system with over one year of clinically proven use.
LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.
Former Senate Majority Leader Tom Daschle, a South Dakota Democrat, tells Kaiser Health News that a Republican strategy to defund the health law may be an effective way for the plan's opponents to unravel it.
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.
› Verified 8 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 99.3 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 98.8 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 99.4 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 92.3 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 95.9 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 99.5 | 96.4 |
News Archive
Mirada Medical, a global leader in Artificial Intelligence software for the treatment of cancer, has announced today further global installations of DLCExpert, the world's first commercially available AI-powered auto contouring software for cancer treatment planning and the only system with over one year of clinically proven use.
LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.
Former Senate Majority Leader Tom Daschle, a South Dakota Democrat, tells Kaiser Health News that a Republican strategy to defund the health law may be an effective way for the plan's opponents to unravel it.
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.
› Verified 8 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 83.8 | 79.6 |
| How often patients got better at getting in and out of bed | 84.7 | 81.1 |
| How often patients got better at bathing | 89.8 | 82.3 |
| How often patients’ breathing improved | 88.6 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 95.7 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 80.9 | 75 |
| How often home health patients had to be admitted to the hospital | 17.6 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 13.2 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 99.4 | 94 |
News Archive
Mirada Medical, a global leader in Artificial Intelligence software for the treatment of cancer, has announced today further global installations of DLCExpert, the world's first commercially available AI-powered auto contouring software for cancer treatment planning and the only system with over one year of clinically proven use.
LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.
Former Senate Majority Leader Tom Daschle, a South Dakota Democrat, tells Kaiser Health News that a Republican strategy to defund the health law may be an effective way for the plan's opponents to unravel it.
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.
› Verified 8 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Mirada Medical, a global leader in Artificial Intelligence software for the treatment of cancer, has announced today further global installations of DLCExpert, the world's first commercially available AI-powered auto contouring software for cancer treatment planning and the only system with over one year of clinically proven use.
LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.
Former Senate Majority Leader Tom Daschle, a South Dakota Democrat, tells Kaiser Health News that a Republican strategy to defund the health law may be an effective way for the plan's opponents to unravel it.
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.
› Verified 8 days ago
The patient survey data of Care First Home Health Care is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 85 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 83 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 74 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 79 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 78 | 78 |
News Archive
Mirada Medical, a global leader in Artificial Intelligence software for the treatment of cancer, has announced today further global installations of DLCExpert, the world's first commercially available AI-powered auto contouring software for cancer treatment planning and the only system with over one year of clinically proven use.
LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.
Former Senate Majority Leader Tom Daschle, a South Dakota Democrat, tells Kaiser Health News that a Republican strategy to defund the health law may be an effective way for the plan's opponents to unravel it.
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.
› Verified 8 days ago
Advisacare Solutions Of Nevada, Inc Location: 1840 E Warm Springs Rd Suite 100, Las Vegas, Nevada 89119 Ratings: Phone: (702) 896-6393 | |
Southwest Medical Associates Home Health Location: 8655 S Eastern Ave, Las Vegas, Nevada 89123 Ratings: Phone: (702) 383-0887 | |
In House Home Health Inc. Location: 3075 East Flamingo Road, Suite #116, Las Vegas, Nevada 89121 Ratings: Phone: (702) 894-9449 | |
Harmony Home Health Location: 820 Rancho Ln #20, Las Vegas, Nevada 89106 Ratings: Phone: (702) 880-7525 | |
Always Better Care Location: 6950 Via Olivero Ave Ste B4, Las Vegas, Nevada 89117 Ratings: Phone: (702) 364-8006 | |
Kindred At Home Location: 9121 West Russell Ste 118, Las Vegas, Nevada 89148 Ratings: Phone: (702) 228-0282 |